Downsizing a human inflammatory protein to a small molecule with equal potency and functionality.

Area of Science:

• Medicinal Chemistry
• Chemical Biology
• Immunology

Background:

• Reproducing protein functional potency in small molecules presents a significant challenge in drug development.
• Synthetic peptides often lack the structural stability and bioavailability required for therapeutic use.
• The human inflammatory protein complement C3a is crucial in innate immunity.

Purpose of the Study:

• To develop a novel method for creating small molecules with protein-like functional potencies.
• To transform the complement C3a protein into equipotent small molecule agonists.
• To enhance stability and bioavailability compared to native proteins and synthetic peptides.

Main Methods:

• Utilized a novel approach starting from a functionally important amino acid of the target protein.
• Employed peptide surrogates incorporating a turn-inducing heterocycle with specific hydrogen-bond-accepting atoms.
• Synthesized small molecule agonists with molecular weight under 500 Da.

Main Results:

• Achieved small molecules with equipotent receptor affinity and cellular responses compared to the native C3a protein.
• Demonstrated high functional profile and specificity of action for the developed small molecules.
• Observed significantly greater plasma stability and bioavailability in the small molecule agonists.

Conclusions:

• Successfully translated the functional potency of a protein (complement C3a) into small molecules (<500 Da).
• The novel approach yields stable, bioavailable small molecules with protein-like efficacy and specificity.
• These findings offer a promising strategy for developing cost-effective, non-immunogenic therapeutics.